Monthly Archives: March 2009

From The Telegraph: Artificial life ‘could be created within five years’ Laboratories across the world are closing in on a “second genesis” – an achievement that would be one of the greatest scientific breakthroughs of all time.Prof David Deamer, from … Continue reading →

From GenomeWeb Daily News: HHS Committee Opens Public Comment on Gene Patents A National Institutes of Health task force has released a draft report on its findings about the effects of gene patenting on medicine, research, and business, and has … Continue reading →

2 new publications out of the McLaughlin-Rotman Centre for Global Health: From Nature Biotech: A survey of South-North health biotech collaboration In recent years, biotech companies in North America and Europe have increasingly looked to developing countries to find new … Continue reading →

From pharmiweb.com: NICE AND GSK GO HEAD-TO-HEAD ON DRUG PRICING AT BUPA HEALTH DEBATE The National Institute for Health and Clinical Excellence (NICE), the body that approves drugs for the NHS, will go head-to-head with pharmaceutical giant GlaxoSmithKline (GSK) on … Continue reading →

Australians refused insurance because of poor genes AUSTRALIANS have been refused insurance protection because of their genetic make-up, researchers have shown in the first study in the world to provide proof of genetic discrimination. Most cases were found to relate … Continue reading →

From Marc Gunther: Geoengineering: Time to get serious? Imagine a fleet of 1,500 remote-controlled, wind-powered ships, sailing the world’s oceans, spewing salt water into the air to whiten clouds, so they block more of the sun and cool an overheating … Continue reading →

From the Organic Consumers’ Association: In this Briefing, we look at how the US’s agricultural reconstruction work in Afghanistan and Iraq not only gives easy entry to US agribusiness and pushes neoliberal policies, something that has always been a primary … Continue reading →

From AlterNet.org: The Case for Giving Eli Lilly the Corporate Death Penalty Eli Lilly & Company’s rap sheet as a public menace is so long that for Lilly watchers to overcome the “banality-of-Lilly-sleaziness” phenomenon, the drug company must break some … Continue reading →

From a few months ago, but a great question: Will biotech change pharma ethics? Big pharma is continuing to absorb the biotech sector, as the drama over ImClone makes clear.…So perhaps it is no coincidence that medical schools are now … Continue reading →

This isn’t a biotech story, but relevant to those in the biotech industry who manufacture medical devices:Wall Street Journal: Political Lobbying Drove FDA Process The recent approval of a new device to treat knee injuries followed a lobbying campaign that … Continue reading →